论文部分内容阅读
目的:分析美沙拉嗪对溃疡性结肠炎患者的治疗效果及安全性,并探讨最佳给药方式。方法:选取107例溃疡性结肠炎患者,随机分为A、B、C 3组,A组36例口服美沙拉嗪,B组36例应用美沙拉嗪口服加灌肠,C组35例作为对照餐后口服柳氮磺吡啶。连续治疗2个月后比较临床疗效、凝血指标与细胞因子水平及不良反应发生情况。结果:3组治疗前后DAI评分差值差异具有统计学意义(F=7.439,P=0.008),B组临床疗效显著优于A、C两组(P=0.045、P=0.004)。B组治疗后的IFN-γ、IL~(-1)、IL-8及Fib水平显著低于A组(t=2.981、2.342、2.318、3.059,P<0.05)。A、B两组的不良反应发生率显著低于C组(Z=3.582、3.168,P<0.01),而A组与B组不良反应情况比较差异无统计学意义(Z=0.512,P>0.05)。结论:美沙拉嗪口服联合灌肠治疗溃疡性结肠炎疗效显著,能明显改善患者炎症情况,且安全性较高。
Objective: To analyze the curative effect and safety of mesalazine on patients with ulcerative colitis and to explore the best way of administration. Methods: A total of 107 patients with ulcerative colitis were selected and randomly divided into A, B and C groups. 36 patients in group A received mesalazine orally, 36 patients in group B received mesalazine plus enema, 35 patients in group C served as control meal After oral sulfasalazine. After 2 months of continuous treatment, the clinical curative effect, coagulation index, cytokine level and the occurrence of adverse reactions were compared. Results: The differences of DAI score between the three groups before and after treatment were statistically significant (F = 7.439, P = 0.008). The clinical efficacy of group B was significantly better than that of group A and C (P = 0.045, P = 0.004). The levels of IFN-γ, IL-1, IL-8 and Fib in group B were significantly lower than those in group A (t = 2.981,2.342,2.318,3.059, P <0.05). The incidence of adverse reactions in groups A and B was significantly lower than that in group C (Z = 3.582, 3.168, P <0.01), but there was no significant difference in adverse reactions between groups A and B (Z = 0.512, P> 0.05 ). Conclusion: Mesalazine combined with enema in the treatment of ulcerative colitis has significant curative effect, which can significantly improve the inflammation of patients and has higher safety.